News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
Pipeline report documents 100M patient addressable market, first-mover economics, and digital therapeutic revenue impact of at least 44% lifetime value increase
Wilmington, Del., Jan 20, 2025 – Hyfe, Inc., the global leader in AI-powered cough care, released a new market intelligence report documenting a substantial commercial opportunity in Refractory Chronic Cough (RCC) therapeutics, where approximately 100 million patients worldwide and 10 million in the U.S. have no access to FDA-approved treatment options. The report, Refractory Chronic Cough Therapeutics: Pipeline Analysis & Competitive Landscape 2026-2035, provides the most detailed competitive assessment of the RCC treatment landscape available.
Currently, the standard of care for RCC patients relies entirely on off-label neuromodulators with 31-40% adverse event rates. This analysis projects the global cough therapeutic market will reach $14-15 billion by 2035 from approximately $9 billion in 2024, representing a 6% compound annual growth rate across the U.S., EU, U.K., and Japan. With major industry signals and regulatory outcomes, such as GSK’s acquisition of Bellus Health and Merck’s Complete Response Letters for Gefapixant, there is clear market validation and regulatory requirements driving the adoption of RCC therapeutics.
The 52-page analysis quantifies market dynamics across regulatory, clinical, and commercial dimensions, evaluating three primary therapeutic approaches including P2X3 Antagonists like Camlipixant, Kappa/Mu Opioid Modulators such as Trevi Therapeutics’ Nalbuphine ER, and Digital Therapeutics like the Kyorin Pharmaceuticals × Hyfe collaboration. It details:
The report concludes the U.S. market will support one, possibly two, meaningfully differentiated therapies based on: temporal separation between approvals, specialist referral bottlenecks limiting rapid market expansion, digital ecosystem lock-in effects once patients engage with monitoring platforms, and payer preference for a single preferred agent absent clear clinical differentiation. Durability of evidence, data integration, and health economics validation will determine market share allocation.
RCC is a widely underserved market, and what stands out in this report is how clearly defined the opportunity has become. We built this analysis to help development and commercial teams understand where differentiation is possible and how real-world care pathways are shaping which therapies can realistically succeed.
Dr. Peter Small
MD, Chief Medical Officer at Hyfe
The complete analysis, including competitive landscape matrices, payer reimbursement frameworks by jurisdiction, and detailed financial models, is available for free at coughreport.com. This research was conducted with financial support from Hyfe Inc. The views and conclusions expressed are those of the authors and do not necessarily reflect the views of Hyfe Inc.
Hyfe, Inc. is the global leader in AI-powered cough-monitoring technology. The company’s patented machine-learning software enables passive, long-term monitoring of cough frequency, revealing novel health insights. Hyfe delivers cough-monitoring solutions that empower pharma and academic researchers to advance clinical trials, enable healthcare providers to optimize patient care, and power digital therapeutics to transform the management of respiratory illness, including chronic cough. Hyfe’s technology has been used in 50+ research studies, and its long-term partners include global pharma companies and leading academic institutions. More information is available at hyfe.com.
###
Media contact:
press@hyfe.com
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.